Meaning lower doses keep their efficacy and avoiding the physiological side effects associated with increasing doses
ZnC is not approved by the Food and Drug Administration (FDA) as a drug for GI conditions
I also observed a worsening of pre-existing POTS symptoms a condition that, in hypermobile Ehlers-Danlos Syndrome, is not incidental but mechanistically downstream: a recognized consequence of defective extracellular matrix that can produce peripheral venous laxity, impaired lower-extremity vasoconstriction, chronic hypovolemia, and the compensatory hyperadrenergic state that characterizes the neuropathic POTS phenotype
The development of nanotechnology-based formulations, such as liposomes and nanophytosomes, has shown great promise in enhancing the solubility, stability, and brain bioavailability of these compounds, thereby maximizing their neuroprotective effects in ASD (Moghaddam et al., 2023
Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis